Thiolanox
Jul 06, 2020
Rising Nontuberculous Mycobacterial Infection Prevalence Poses A Major Public Health Concern
The Nontuberculous mycobacterial infection market worth is expected to grow at a CAGR of 6.6% by 2030 owing to robust NTM infection pipeline, rising prevalence among immunocompromised as well as immunocompetent populations, and a considerable shift towards branded therapeutics options. Planet Earth hosts a dive...
Read More...
Feb 05, 2020
Nontuberculous Mycobacteria Infection Market: Current status of NTM infection drug discovery and development
Nontuberculous mycobacteria (NTM) are members of the Mycobacterium genus other than Mycobacterium tuberculosis complex and Mycobacterium leprae. NTM is a significant cause of chronic lung disease in immunosuppressed individuals and people suffering from chronic lung diseases such as chronic obstructive pulmonary di...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
